Parkinson’s Disease. It is a chronic, progressive movement disorder in which symptoms continue and get worse with time. Parkinson’s is characterized by death of essential nerve cells/neurons. This disease primarily affects neurons in the susbstantia nigra area of the brain. Few of the dying neurons produce dopamine, which sends messages to that part of the brain which controls movement. Parkinson's disease (PD) is a type of movement disorder. It happens when nerve cells in the brain don't produce enough of a brain chemical called dopamine. Sometimes it is genetic, but most cases do not seem to run in families. Exposure to chemicals in the environment might play a role.

Parkinson’s disease;  Non-motor symptoms; Depression; Istradefylline; Adenosine A 2A antagonist. Introduction. A selective adenosine A 2A receptor antagonist, istradefylline (ISD), is the one of novel drugs for Parkinson’s disease (PD). The clinical efficacy of ISD for motor fluctuations in advanced PD patients was proved.

Parkinsonâ⠬⠢s Disease Therapeutics market report emphasizes the adoption pattern of the Parkinsonâ⠬⠢s Disease Therapeutics across various industries. The Parkinsonâ⠬⠢s Disease Therapeutics market report examines the operating pattern of each player – new product launches, partnerships, and acquisitions